Analyst Swayampakula Ramakanth from H.C. Wainwright reiterated a Buy rating on Pyxis Oncology and keeping the price target at $5.00.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Swayampakula Ramakanth has given his Buy rating due to a combination of factors including the upcoming clinical data updates and the financial outlook of Pyxis Oncology. The company is expected to present preliminary clinical data from their Phase 1 monotherapy program for MICVO in relapsed/metastatic head and neck cancer by the end of 2025, which could provide significant insights into the drug’s efficacy and potential market impact.
Additionally, recent translational data has shown promising anti-tumor activity for MICVO, highlighting its ability to target and kill tumor cells effectively. Financially, Pyxis Oncology reported a substantial cash reserve, which is anticipated to support operations into the second half of 2026, and the valuation analysis suggests a favorable risk-adjusted net present value. These factors collectively underpin the Buy rating with a 12-month price target of $5.00 per share.
According to TipRanks, Ramakanth is a 5-star analyst with an average return of 22.5% and a 45.11% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Corcept Therapeutics, Evaxion Biotech, and Delcath Systems.